{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T09:28:30Z","timestamp":1769160510073,"version":"3.49.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82103146"],"award-info":[{"award-number":["82103146"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017683","name":"Dalian Science and Technology Innovation Fund","doi-asserted-by":"publisher","award":["2024RY004"],"award-info":[{"award-number":["2024RY004"]}],"id":[{"id":"10.13039\/501100017683","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012465","name":"Dalian Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012465","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ejphar.2025.178105","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T06:55:19Z","timestamp":1756450519000},"page":"178105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["HSP90 inhibition induces oncogenic EGF receptor degradation to suppress cell growth in non-small cell lung cancer"],"prefix":"10.1016","volume":"1005","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-2905-7855","authenticated-orcid":false,"given":"Yue","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinhao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Le","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaoxuan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaowen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinghui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jialiang","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingqiu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaoxia","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ejphar.2025.178105_bib1","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1593\/neo.12986","article-title":"Wild-type EGF receptor is stabilized by direct interaction with HSP90 in cancer cells and tumors","volume":"14","author":"Ahsan","year":"2012","journal-title":"Neoplasia"},{"key":"10.1016\/j.ejphar.2025.178105_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110434","article-title":"Low dose HSP90 inhibition with AUY922 blunts rapid evolution of metastatic and drug resistant phenotypes induced by TGF-Beta and paclitaxel in A549 cells","volume":"129","author":"Bacon","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejphar.2025.178105_bib3","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1146\/annurev-biochem-060815-014659","article-title":"Spatial and temporal regulation of receptor tyrosine kinase activation and intracellular signal transduction","volume":"85","author":"Bergeron","year":"2016","journal-title":"Annu. Rev. Biochem."},{"issue":"12","key":"10.1016\/j.ejphar.2025.178105_bib4","doi-asserted-by":"crossref","first-page":"4231","DOI":"10.1080\/15548627.2021.1909835","article-title":"TRIM28 functions as a negative regulator of aggresome formation","volume":"17","author":"Chang","year":"2021","journal-title":"Autophagy"},{"key":"10.1016\/j.ejphar.2025.178105_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.765115","article-title":"Plasmatic levels of HSP90\u03b1 at diagnosis: a novel prognostic indicator of clinical outcome in advanced lung cancer patients treated with PD-1\/PD-L1 inhibitors plus chemotherapy","volume":"11","author":"Chen","year":"2021","journal-title":"Front. Oncol."},{"issue":"19","key":"10.1016\/j.ejphar.2025.178105_bib6","doi-asserted-by":"crossref","first-page":"5825","DOI":"10.7150\/jca.56640","article-title":"SNX-2112 induces apoptosis and inhibits proliferation, invasion, and migration of non-small cell lung cancer by downregulating epithelial-mesenchymal transition via the wnt\/Beta-catenin signaling pathway","volume":"12","author":"Cheng","year":"2021","journal-title":"J. Cancer"},{"issue":"3","key":"10.1016\/j.ejphar.2025.178105_bib7","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.devcel.2012.08.011","article-title":"Governance of endocytic trafficking and signaling by reversible ubiquitylation","volume":"23","author":"Clague","year":"2012","journal-title":"Dev. Cell"},{"issue":"6","key":"10.1016\/j.ejphar.2025.178105_bib8","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41580-019-0099-1","article-title":"Breaking the chains: deubiquitylating enzyme specificity begets function","volume":"20","author":"Clague","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"4","key":"10.1016\/j.ejphar.2025.178105_bib9","doi-asserted-by":"crossref","first-page":"340","DOI":"10.21037\/tlcr.2019.08.22","article-title":"Hsp90 inhibitors enhance the antitumoral effect of osimertinib in parental and osimertinib-resistant non-small cell lung cancer cell lines","volume":"8","author":"Codony-Servat","year":"2019","journal-title":"Transl. Lung Cancer Res."},{"issue":"10","key":"10.1016\/j.ejphar.2025.178105_bib10","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1039\/D4MD00384E","article-title":"Next-generation EGF receptor tyrosine kinase inhibitors to overcome C797S mutation in non-small cell lung cancer (2019-2024)","volume":"15","author":"Das","year":"2024","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejphar.2025.178105_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105583","article-title":"EGF receptor mutation mediates resistance to EGF receptor tyrosine kinase inhibitors in NSCLC: from molecular mechanisms to clinical research","volume":"167","author":"Dong","year":"2021","journal-title":"Pharmacol. Res."},{"issue":"6","key":"10.1016\/j.ejphar.2025.178105_bib12","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1021\/acssensors.3c00216","article-title":"Integrated imaging and proteomic sensors resolve proteome aggregation in liver caused by non-steroidal anti-inflammatory drug overdose","volume":"8","author":"Dong","year":"2023","journal-title":"ACS Sens."},{"issue":"31","key":"10.1016\/j.ejphar.2025.178105_bib13","doi-asserted-by":"crossref","first-page":"28950","DOI":"10.1074\/jbc.M304474200","article-title":"Cbl-mediated ubiquitinylation is required for lysosomal sorting of epidermal growth factor receptor but is dispensable for endocytosis","volume":"278","author":"Duan","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.ejphar.2025.178105_bib14","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41388-019-1016-y","article-title":"Heat-shock proteins: chaperoning DNA repair","volume":"39","author":"Dubrez","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.ejphar.2025.178105_bib15","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.2147\/JIR.S401444","article-title":"Predictive value of serum heat shock protein 90\u03b1 on the prognosis of patients with lung adenocarcinoma","volume":"16","author":"Fang","year":"2023","journal-title":"J. Inflamm. Res."},{"issue":"15","key":"10.1016\/j.ejphar.2025.178105_bib16","doi-asserted-by":"crossref","first-page":"11219","DOI":"10.1074\/jbc.M109.042754","article-title":"The microtubule-associated histone deacetylase 6 (HDAC6) regulates epidermal growth factor receptor (EGF receptor) endocytic trafficking and degradation","volume":"285","author":"Gao","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.ejphar.2025.178105_bib17","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1034\/j.1600-0854.2002.30602.x","article-title":"Hassles with taking out the garbage: aggravating aggresomes","volume":"3","author":"Garcia-Mata","year":"2002","journal-title":"Traffic"},{"issue":"25","key":"10.1016\/j.ejphar.2025.178105_bib18","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1200\/JCO.2016.66.9929","article-title":"Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer","volume":"34","author":"Gettinger","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.ejphar.2025.178105_bib19","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1007\/s00018-016-2255-5","article-title":"The recognition of ubiquitinated proteins by the proteasome","volume":"73","author":"Grice","year":"2016","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejphar.2025.178105_bib20","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.semcancer.2019.09.015","article-title":"Rare epidermal growth factor receptor (EGF receptor) mutations in non-small cell lung cancer","volume":"61","author":"Harrison","year":"2020","journal-title":"Semin. Cancer Biol."},{"issue":"6","key":"10.1016\/j.ejphar.2025.178105_bib21","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0092-8674(03)00939-5","article-title":"The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress","volume":"115","author":"Kawaguchi","year":"2003","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.ejphar.2025.178105_bib22","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1083\/jcb.200810114","article-title":"K63-linked ubiquitin chains as a specific signal for protein sorting into the multivesicular body pathway","volume":"185","author":"Lauwers","year":"2009","journal-title":"J. Cell Biol."},{"issue":"17","key":"10.1016\/j.ejphar.2025.178105_bib23","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1200\/JCO.2014.58.1736","article-title":"Impact of specific epidermal growth factor receptor (EGF receptor) mutations and clinical characteristics on outcomes after treatment with EGF receptor tyrosine kinase inhibitors versus chemotherapy in EGF receptor-mutant lung cancer: a meta-analysis","volume":"33","author":"Lee","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.ejphar.2025.178105_bib24","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell signaling by receptor tyrosine kinases","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.ejphar.2025.178105_bib25","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.jtho.2018.03.035","article-title":"A phase II study of pembrolizumab in EGF receptor-Mutant, PD-L1+, tyrosine kinase inhibitor na\u00efve patients with advanced NSCLC","volume":"13","author":"Lisberg","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"8","key":"10.1016\/j.ejphar.2025.178105_bib26","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.neo.2015.08.002","article-title":"EGF receptor regulates the development and microarchitecture of intratumoral angiogenic vasculature capable of sustaining cancer cell intravasation","volume":"17","author":"Minder","year":"2015","journal-title":"Neoplasia"},{"key":"10.1016\/j.ejphar.2025.178105_bib27","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.phrs.2017.01.003","article-title":"Targeting EGF receptor T790M mutation in NSCLC: from biology to evaluation and treatment","volume":"117","author":"Passaro","year":"2017","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178105_bib28","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1677\/erc.0.0080011","article-title":"The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification","volume":"8","author":"Prenzel","year":"2001","journal-title":"Endocr. Relat. Cancer"},{"issue":"Suppl. l_1","key":"10.1016\/j.ejphar.2025.178105_bib29","doi-asserted-by":"crossref","first-page":"i20","DOI":"10.1093\/annonc\/mdx704","article-title":"Osimertinib and other third-generation EGF receptor TKI in EGF receptor-mutant NSCLC patients","volume":"29","author":"Remon","year":"2018","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.ejphar.2025.178105_bib30","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1158\/0008-5472.CAN-07-5989","article-title":"Role of the aggresome pathway in cancer: targeting histone deacetylase 6-dependent protein degradation","volume":"68","author":"Rodriguez-Gonzalez","year":"2008","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.ejphar.2025.178105_bib31","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGF receptor mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol."},{"issue":"27","key":"10.1016\/j.ejphar.2025.178105_bib32","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGF receptor mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ejphar.2025.178105_bib33","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrc2088","article-title":"Epidermal growth factor receptor mutations in lung cancer","volume":"7","author":"Sharma","year":"2007","journal-title":"Nat. Rev. Cancer"},{"issue":"18","key":"10.1016\/j.ejphar.2025.178105_bib34","doi-asserted-by":"crossref","first-page":"4973","DOI":"10.1158\/1078-0432.CCR-11-2967","article-title":"Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer","volume":"18","author":"Shimamura","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.ejphar.2025.178105_bib35","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGF receptor-Mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178105_bib36","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/s42003-021-02906-4","article-title":"A small-molecule compound D6 overcomes EGF receptor-T790M-mediated resistance in non-small cell lung cancer","volume":"4","author":"Tang","year":"2021","journal-title":"Commun. Biol."},{"issue":"17","key":"10.1016\/j.ejphar.2025.178105_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/cells11172664","article-title":"The role of the heat-shock proteins in esophagogastric cancer","volume":"11","author":"Tustumi","year":"2022","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.ejphar.2025.178105_bib38","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1021\/acs.analchem.0c04309","article-title":"Monitoring the dynamics of proteome aggregation in live cells using a solubilized and noncovalent analogue of fluorescent protein chromophores","volume":"93","author":"Wan","year":"2021","journal-title":"Anal. Chem."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178105_bib39","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12964-018-0245-y","article-title":"The exon 19-deleted EGF receptor undergoes ubiquitylation-mediated endocytic degradation via dynamin activity-dependent and -independent mechanisms","volume":"16","author":"Wang","year":"2018","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.ejphar.2025.178105_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107491","article-title":"Chemical sensors detect and resolve proteome aggregation in peripheral neuropathy cell model induced by chemotherapeutic agents","volume":"148","author":"Wang","year":"2024","journal-title":"Bioorg. Chem."},{"issue":"5","key":"10.1016\/j.ejphar.2025.178105_bib41","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/1759-7714.13839","article-title":"HSP90 inhibition overcomes EGF receptor amplification-induced resistance to third-generation EGF receptor-TKIs","volume":"12","author":"Watanabe","year":"2021","journal-title":"Thorac. Cancer"},{"issue":"5","key":"10.1016\/j.ejphar.2025.178105_bib42","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ccr.2008.03.015","article-title":"Survival of cancer cells is maintained by EGF receptor independent of its kinase activity","volume":"13","author":"Weihua","year":"2008","journal-title":"Cancer Cell"},{"issue":"13","key":"10.1016\/j.ejphar.2025.178105_bib43","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1158\/0008-5472.CAN-11-3720","article-title":"Combined EGF receptor\/MET or EGF receptor\/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGF receptor containing T790M and MET","volume":"72","author":"Xu","year":"2012","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.ejphar.2025.178105_bib44","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1128\/MCB.00103-14","article-title":"Proteasome failure promotes positioning of lysosomes around the aggresome via local block of microtubule-dependent transport","volume":"34","author":"Zaarur","year":"2014","journal-title":"Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178105_bib45","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41392-022-00966-4","article-title":"Targeted protein degradation: mechanisms, strategies and application","volume":"7","author":"Zhao","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejphar.2025.178105_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176387","article-title":"HSP90: a promising target for NSCLC treatments","volume":"967","author":"Zhu","year":"2024","journal-title":"Eur. J. Pharmacol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925008593?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925008593?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:33:17Z","timestamp":1762144397000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299925008593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":46,"alternative-id":["S0014299925008593"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178105","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HSP90 inhibition induces oncogenic EGF receptor degradation to suppress cell growth in non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178105","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"178105"}}